Target Group Valuation

Q: What is the Fair Price of CBDY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CBDY ($0) is trading below our estimate of [[fair value]] ($0.19)

Is CBDY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CBDY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CBDY ($0) is trading below our estimate of fair value ($0.19)

Significantly Below Fair Value: CBDY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CBDY?

Key metric: As CBDY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CBDY. This is calculated by dividing CBDY's market cap by their current revenue.
What is CBDY's PS Ratio?
PS Ratio	0.2x
Sales	US$6.65m
Market Cap	US$1.48m

CBDY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.7x
Enterprise Value/EBITDA	6.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CBDY's PS Ratio compare to its peers?

The above table shows the PS ratio for CBDY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2x
GSAC GelStat	5.6x	n/a	US$897.1k
BSPK Bespoke Extracts	1.1x	n/a	US$1.2m
KOAN Resonate Blends	0.7x	n/a	US$502.0k
SPRC SciSparc	0.5x	n/a	US$1.0m
CBDY Target Group	0.2x	n/a	US$1.5m

Price-To-Sales vs Peers: CBDY is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does CBDY's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

74 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	2.6x	10.1%
CBDY Target Group	0.2x	n/a	US$1.48m
OGN Organon	0.6x	-0.06%	US$3.83b
PRGO Perrigo	0.9x	3.4%	US$3.69b

74 Companies		Estimated Growth	Market Cap
Industry Avg.	2.6x	23.7%
CBDY Target Group	0.2x	n/a	US$1.48m

No more companies

Price-To-Sales vs Industry: CBDY is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Pharmaceuticals industry average (2.5x).

Price to Sales Ratio vs Fair Ratio

What is CBDY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CBDY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CBDY's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$35.9b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

4.7%

-4.8%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

0.6%

9.8%